Inhibition of angiogenesis by vitamin D-binding protein: Characterization of anti-endothelial activity of DBP-maf

Angiogenesis

Volumn 8, Issue 4, 2006, Pages 349-360

  Kalkunte, Satyan ^a   Brard, Laurent ^a,b   Granai, Cornelius O ^a   Swamy, Narasimha ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Angiogenesis; DBP maf; Endothelial cells; ERK1 2; VEGF

Indexed keywords

MACROPHAGE ACTIVATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHTHALIC ACID DIBUTYL ESTER; PROTEIN KINASE B; VASCULOTROPIN; VITAMIN D BINDING PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL MIGRATION; DNA SYNTHESIS; DRUG ACTIVITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IC 50; INFORMATION PROCESSING; MICROVASCULATURE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SPROUTING; TUMOR GROWTH; VASCULAR RING;

CELL MIGRATION INHIBITION; CELL PROLIFERATION; CELLS, CULTURED; DNA REPLICATION; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; G1 PHASE; GROWTH INHIBITORS; HUMANS; MACROPHAGE-ACTIVATING FACTORS; MICROVESSELS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; S PHASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN D-BINDING PROTEIN;

ANIMALIA;

EID: 33644597131     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-005-9024-7     Document Type: Article

References (47)

1. Flamme I, Frolich T, Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol 1997; 173: 206-10.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
3. Polverini PJ. Angiogenesis in health and disease: Insights into basic mechanisms and therapeutic opportunities. J Dent Educ 2002; 66: 962-75.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
5. Polverini PJ. The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 1995; 6: 230-47.
6. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-7.
7. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-88.
8. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
9. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol 2002; 55: 348-59.
10. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
11. Ribatti D, Vacca A, Nico B et al. Angiogenesis and anti-angiogenesis in neuroblastoma. Eur J Cancer 2002; 38: 750-7.
12. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
13. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med 1989; 320: 1211-2.
14. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
15. Brem S. Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control 1999; 6: 436-58.
16. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
17. Gourley M. Williamson JS. Angiogenesis: New targets for the development of anticancer chemotherapies. Curr Pharm Des 2000; 6: 417-39.
18. Ellis LM, Liu W, Ahmad SA et al. Overview of angiogenesis: Biologic implications for antiangiogenic therapy. Semin Oncol 2001; 28: 94-104.
19. O'Reilly MS, Rosenthal R, Sage EH et al. The suppression of tumor metastases by a primary tumor. Surg Forum 1993; 44: 474-6.
20. Kisker O, Onizuka S, Becker CM et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003; 5: 32-40.
21. Yamamoto N, Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. J Immunol 1993; 151: 2794-802.
22. Swamy N, Ghosh S, Schneider GB, Ray R. Baculovirus-expressed vitamin D-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts and binding of 25-hydroxyvitamin D(3) does not influence this activity. J Cell Biochem 2001; 81: 535-46.
23. Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 2004; 22: 340-5.
24. Gumireddy K, Reddy CD, Swamy N. Mitogen-activated protein kinase pathway mediates DBP-maf-induced apoptosis in RAW 264.7 macrophages. J Cell Biochem 2003; 90: 87-96.
25. Malich G, Markovic B, Winder C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 1997; 124: 179-92.
26. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 1982; 218: 474-5.
27. Ormerod MG (eds.). A Practical Approach in Flow Cytometry. New York: Oxford University Press 1990 69-81.
28. Lee OH, Kim YM, Lee YM et al. Sphingosine 1-phosphate induces angiogenesis: Its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 1999; 264: 743-50.
29. Ashton AW, Yokota R, John G et al. Inhibition of endothelial cell migration, intercellular communication and vascular tube formation by thromboxane A2. J Biol Chem 1999; 274: 35562-70.
30. Nicosia RF, Ottinetti A. Growth of microvessels in serumfree matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990; 63: 115-22.
31. Murry JC. Angiogenesis Protocols. In Murry JC (ed.), Methods in Molecular Medicine. Vol. 46. Totowa, NJ: Humana Press Scientific and Medical Publishers, 2001; 185-204.
32. Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol 1984; 99: 2034-40.
33. Kanda S, Tomasini-Johanson B, Klint P et al. Signaling via fibroblast growth factor receptor-1 is dependent on extracellular matrix in capillary endothelial cell differentiation. Exp Cell Res 1999; 248: 203-13.
34. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990; 63: 115-22.
35. Devy L, Blacher S, Grignet-Debrus C et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16: 147-54.
36. Meyer RD, Rahimi N. Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems? Ann NY Acad Sci 2003; 995: 200-7.
37. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
38. Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 1997; 272: 15442-51.
39. Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 2004; 22: 340-5.
40. Zachary I. VEGF signalling: Integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003; 117: 1-7.
41. Cirri L, Donnini S, Morbidelli L et al. Endostatin: A promising drug for antiangiogenic therapy. Int J Biol Markers 1999; 14: 263-7.
42. Maione TE, Gray GS, Petro J et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247: 77-9.
43. Kusaka M, Sudo K, Matsutani E et al. Cytostatic inhibition of endothelial-cell growth by angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69: 212-6.
44. Gentilini G, Kirschbaum NE, Augustine JA et al. Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). Blood 1999; 93: 25-33.
45. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13: 159-67.
46. Bailar JC 3rd, Gornik HL. Cancer undefeated. N Engl J Med 1997; 336: 1569-74.
47. Klohs WD, Hamby JM. Antiangiogenic agents. Curr Opin Biotechnol 1999; 10: 544-9.